The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
Status:
RECRUITING
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, open-label, placebo-controlled, dose-escalation trial. The objective of this research is to evaluate the safety, tolerability, and efficacy of intrathecal administration of human-induced neural stem cell-derived extracellular vesicles (NouvSoma001) for the treatment of neuromyelitis optica spectrum disorders.